Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312325 | 0.94 | TSHR (0.58) | TSHRKCNJ1KCNH2LOXL2SIRT2 | |
| SCHEMBL7943874 | 0.92 | KCNH2 (0.59) | TSHRKCNJ1KCNH2LOXL2SIRT2 | |
| SCHEMBL77658 | 0.88 | TSHR (0.64) | TSHRKCNJ1KCNH2LOXL2HRH3 | |
| SCHEMBL30758863 | 0.87 | TSHR (0.69) | TSHRKCNJ1KCNH2LOXL2HRH3 | |
| SCHEMBL18913824 | 0.87 | TSHR (0.69) | TSHRKCNJ1KCNH2LOXL2HRH3 | |
| SCHEMBL1310286 | 0.84 | KCNH2 (0.51) | TSHRKCNJ1KCNH2LOXL2SIRT2 | |
| SCHEMBL3292782 | 0.83 | TSHR (0.75) | TSHRKCNJ1KCNH2LOXL2HRH3 | |
| SCHEMBL7317557 | 0.82 | TSHR (0.62) | TSHRKCNJ1KCNH2LOXL2HRH3 | |
| SCHEMBL9762640 | 0.81 | TSHR (0.49) | TSHRKCNJ1KCNH2LOXL2SIRT2 | |
| SCHEMBL1312040 | 0.80 | TSHR (0.47) | TSHRKCNJ1KCNH2LOXL2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| CN-118255726-A | P-SCN-NOTA type bifunctional chelating agent and synthesis method thereof | 西安福诺医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-117925256-A | Liquid crystal alignment agent, method for producing same, liquid crystal alignment film, and liquid crystal display element | 奇美实业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117580592-A | Compounds for targeting bruton's tyrosine kinase degradation | 渤健马萨诸塞州股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-10842893-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2020-11-24 | — | — | US | disclosed |
| CN-110950781-A | Novel diamine, polyamic acid, and polyimide | 日产化学工业株式会社 | 2020-04-03 | — | — | CN | disclosed |
| US-10556873-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2020-02-11 | — | — | US | disclosed |
| US-10441669-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-10-15 | — | — | US | disclosed |
| EP-0479601-A2 | Piperidine derivatives and their use as antiarrhythmic agents | Ajinomoto Co., Inc. (JP) | 1992-04-08 | — | — | EP | disclosed |
| EP-0454498-A2 | Pyrimidinedione derivatives and antiarrhythmic agents containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-5008267-A | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-04-16 | — | — | US | disclosed |
| EP-0369627-A2 | Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-23 | — | — | EP | disclosed |
| US-4206144-A | N,N-Dialkyl-N-aminoalkyl-N-(amino or nitro)phenylalkyl- and N-methyl-N-[3-(amino or nitro)phenoxy-2-hydroxy-1-propyl]-N,N-bis(3-aminopropyl)quaternary ammonium salts | STERLING DRUG INC. (US) | 1980-06-03 | — | — | US | disclosed |
| US-4146558-A | Azo dyestuff intermediate nitro- or aminobenzenes ring-substituted by a quaternized amine alkyl or amino-alkoxy group | STERLING DRUG INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4103092-A | Water-soluble quaternary ammonium non-heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4065500-A | Water-soluble quaternary ammonium azo dyestuffs | STERLING DRUG INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-3996282-A | Water-soluble quaternary ammonium dyestuffs | STERLING DRUG INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3935182-A | Water-soluble quaternary ammonium heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556873-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, CLTA | TSHR 465/4885KCNJ1 4733/4885KCNH2 3435/4885 |
| US-10842893-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | FECH, SLC40A1, TFRC | TSHR 3803/4885KCNJ1 3900/4885KCNH2 4384/4885 |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | TSHR 3544/4885KCNJ1 4760/4885KCNH2 4730/4885 |
| US-10441669-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | FECH, SLC40A1, TFRC | TSHR 3803/4885KCNJ1 3900/4885KCNH2 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.